These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8172187)

  • 1. Successful treatment of low dose cytosine arabinoside for acute myelofibrosis with immature myeloblast (AML-MO).
    Kanamori H; Tanabe J; Koike T; Hashimoto Y; Matsuzaki M; Kitamura H; Motomura S; Mohri H; Ohkubo T
    Am J Hematol; 1994 Jun; 46(2):154-5. PubMed ID: 8172187
    [No Abstract]   [Full Text] [Related]  

  • 2. Low dose cytosine arabinoside used to induce remission in acute myelofibrosis.
    Whitehead S; Geary CG
    Br J Haematol; 1984 Oct; 58(2):375-6. PubMed ID: 6477839
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment with intermediate dose cytosine arabinoside for myelodysplastic syndrome with acute myelofibrosis.
    Takabayashi M; Sakai R; Kanamori H; Ishigatsubo Y
    Leuk Lymphoma; 2003 May; 44(5):891-2. PubMed ID: 12802934
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose cytosine arabinoside therapy in a patient with myelofibrosis during transformation to acute non-lymphocytic leukemia.
    Jensen MK; Johansen P; Ahlbom G
    Acta Med Scand; 1986; 219(1):129-31. PubMed ID: 3953312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose cytosine arabinoside in the treatment of myeloid leukaemias and myelodysplastic syndromes.
    Murray M; Sarsfield P; Lawlor E; McCann SR
    Ir J Med Sci; 1988 Jul; 157(7):238-41. PubMed ID: 3170148
    [No Abstract]   [Full Text] [Related]  

  • 6. [Megakaryoblastic leukemia (acute myelofibrosis): complete remission of a case with low-dose cytosine arabinoside].
    Palomera L; García Díez I; Woessner S; Velasco F; Torres A
    Sangre (Barc); 1988 Jun; 33(3):232-7. PubMed ID: 3175820
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful low-dose cytosine arabinoside treatment in a patient with acute leukemia from idiopathic myelofibrosis.
    Kobayashi S; Sakai H; Tomiazwa T; Koiso H; Kim K; Ueki K; Tamura J; Yano S; Naruse T; Karasawa M
    J Med; 1999; 30(1-2):101-9. PubMed ID: 10515246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive polychemotherapy for acute myelofibrosis.
    Hertenstein B; Kurrle E; Frickhofen N; Heil G; Heimpel H
    Eur J Haematol; 1990 Apr; 44(4):213-9. PubMed ID: 2344883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of dysmyelopoietic/leukemic syndromes with myelofibrosis and megakaryocytic hyperplasia with large doses of cytosine arabinoside.
    Preisler HD; Raza A; Barcos M
    Med Oncol Tumor Pharmacother; 1985; 2(2):87-91. PubMed ID: 4058079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extensive myelofibrosis responsive to treatment for acute erythroblastic leukaemia.
    Fadilah SA; Raja-Zahratul-Azma RS; Leong CF
    Malays J Pathol; 2006 Jun; 28(1):55-8. PubMed ID: 17694960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia.
    Sanz MA; Martínez J; Borrego D; Martín-Aragonés G; Lorenzo I; Sanz G; Sayas MJ; Jarque I; Pastor E; Rafecas J
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):18-20. PubMed ID: 3589692
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose cytosine arabinoside in the consolidation therapy of acute nonlymphocytic leukemia in remission.
    Takaku F; Urabe A; Mizoguchi H; Hoshino S; Toyama K; Tanaka K; Nomura T; Dan K; Fujioka S; Saito T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):55-7. PubMed ID: 3589698
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
    Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
    Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia.
    Estey E; Plunkett W; Dixon D; Keating M; McCredie K; Freireich EJ
    Leukemia; 1987 Aug; 1(8):580-3. PubMed ID: 3669771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.
    Winer ES; Miller KB; Chan GW
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):11-4. PubMed ID: 15934494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia].
    Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G
    Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine.
    Lu Q; Chen Y; Li Z
    Leuk Res; 2012 Jun; 36(6):e119-21. PubMed ID: 22386731
    [No Abstract]   [Full Text] [Related]  

  • 18. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients.
    Di Febo A; Laurenti L; Falcucci P; Tosti ME; Fianchi L; Pagano L; Leone G
    Am J Ther; 2007; 14(4):351-5. PubMed ID: 17667210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia.
    Hines JD; Mazza JJ; Oken MM; Adelstein DJ; Keller A; Bennett JM; O'Connell MJ
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):37-9. PubMed ID: 3296207
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.